ftInvstr

SAKAR · Healthcare ₹1027.0 +2.27% Mkt Cap ₹2246 Cr overvalued

SAKAR

Healthcare Drug Manufacturers - Specialty & Generic

★ Watchlist ⧉ Add to bucket

₹1027.0

+2.27% today · 30d +3.74%

as of 2026-11-09

Price · Daily Candles

Detect candlestick pattern

AI narrative is temporarily unavailable for SAKAR. The deterministic sections below render from live data.

₹ Latest Earnings · Q ending 2026-09-30

REVENUE

₹87 Cr

+51.87% YoY

NET PROFIT

₹11 Cr

+149.06% YoY

OPM

28.08%

+6.7pp YoY

EPS

₹5.08

PE 78.23

Intrinsic value · DCF ₹352.10 · Margin of safety -65.7% (overvalued) · FCF yield 2.19%

◇ Sector Position

PEERPEROCE %

SAKAR78.2313.0

SUNPHARMA37.7921.44

DIVISLAB93.121.56

ZYDUSLIFE28.424.22

+ 2 more peers — sign in to view

ML Forward Growth Predictions 🔒

9 ML-predicted forward-growth ranks across sales, EBIT, and FCF.

SCORE / 100

Overall

6-axis composite of the sections below.

Performance STRONG 100

Valuation STRETCHED 20

Growth STRONG 82

Profitability HIGH 75

Technicals NEUTRAL 62

Risk LOW 90

Key Stats

TTM PE

78.23

P/B

6.92

52W HIGH

₹1229.85

OFF HIGH

-16.49%

DIV YIELD

0.0%

MKT CAP

₹2246 Cr

◉ Active Signals

MACDNeutral11.1534

RSI(14)Neutral54.47

Street Consensus

1 analyst

₹1020.0

mean target

Low ₹1020.0Now ₹1027.0High ₹1020.0

⧉ Strategy Fit 🔒

See which of ftInvstr's 50+ strategies hold SAKAR and at what entry.